Explore it now
27th Annual ESGO 2026 Congress
Discover it Now!
ENGOT coordinates and promotes gynaecological cancer clinical trials in Europe
Explore ENGOT
Explore ESGO’s Membership Benefits
Read More
Established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer, the ESGO Prevention Committee connects more than 70 experts in vaccination, screening, colposcopy, and treatment of pre-invasive disease.
Apart from Prevention webinars, the Prevention Committee produces consensus statements on prevention-related topics. Visit the ESGO Prevention Committee website to learn more about the research we do.
Prof. Murat Gultekin chairs the Committee.
September 10, 2025 7-8:30 PM CET
Moderators: Annette Hasenburg, Murat Gultekin
Webinar abstract:
This webinar will focus on key aspects of psycho-oncology relevant to clinical practice, exploring how healthcare professionals can support and enhance the quality of life of cancer patients throughout the disease trajectory. Discussions will address whether long-term psychological and physical effects of treatment can be anticipated or prevented, and how early supportive interventions may impact survivorship. A central theme will be the concept of resilience—both in patients facing the emotional and physical challenges of cancer, and in healthcare providers navigating the demands of oncology care. Through evidence-based insights and practical strategies, the session aims to equip clinicians with tools to foster well-being, promote adaptive coping, and sustain compassionate care in the face of long-term challenges. The webinar will close with a powerful patient perspective in the presentation "From scars to connection – reclaiming sexual identity after cancer", offering an intimate and honest reflection on healing, identity, and the importance of communication and empathy in survivorship care.
July 9, 2025 7-8:30 PM CET
Moderators: Rita Sousa, Murat Gultekin
The session highlights newly available HPV vaccines and their potential impact, as well as the growing body of evidence supporting simplified vaccination schedules, including single-dose strategies. Speakers examine current trends in screening, such as risk-based approaches and the application of high-risk HPV assays that have been validated for primary screening. Special attention will be given to the validation principles required for HPV tests, and to assays that target a limited number of HPV types, exploring their potential role in future screening programs. This webinar offers a comprehensive overview for clinicians, researchers, and public health professionals interested in the evolving landscape of HPV prevention and control.
Moderator: Jalid Sehouli
Moderator: Elmar Joura
Moderator: Murat Gultekin
Moderator: Mario Preti
Moderator: Reda Hemida
This is the second edition of a successful full-day virtual event that attracted 1300+ registered participants in 2024. It is focused on vaccination, screening, colposcopy, and treatment of pre-invasive disease in a limited-resource context.
Check out the programme for more details (available in PDF here):
November 11, 2025 7-8:30 PM CET
Moderators: Mihaela Grigore, Murat Gultekin
This webinar will explore the evolving landscape of oncogenetics with a focus on genetic testing and its role in cancer risk assessment, prevention, and personalized care in gynecologic oncology. Experts will discuss the latest advances in genetic screening, including the clinical application of BRCA and Lynch syndrome testing, as well as the emergence of new preventive testing kits now available on the market. A special emphasis will be placed on the gynecologic implications of Lynch syndrome, particularly the elevated risks for endometrial and ovarian cancers and the strategies for risk-reducing management. The program will also delve into recent findings from genome-wide association studies (GWAS) that shed light on genetic variation in cervical preinvasive and invasive disease, expanding our understanding of inherited susceptibility beyond traditional markers. This session will provide clinicians, genetic counselors, and researchers with valuable insights into how genetic information can inform screening decisions, guide preventive strategies, and shape the future of personalized cancer care.